TNFRSF4 and head and neck squamous cell carcinoma: An OX40 agonistic humanized monoclonal antibody (MEDI0562) has also been shown to have a tolerable safety profile and measurable immune-related responses in a phase I trial (NCT02318394) on 55 patients with heavily pre-treated solid tumors (including 26 HNSCC) [147].